多替阿巴拉米片进入医保吗

Have you entered medical insurance? For patients, the inclusion of drugs in medical insurance means that the burden can be reduced. As for the medical insurance issue of Dolutegra Abalamid Tablets, there are no clear regulations for the time being, so patients still need to wait. my country began to implement the "Four Frees and One Care" policy in 2003. In 2006, the policy was institutionalized and legalized through the "Regulations on the Prevention and Treatment of AIDS", which greatly reduced the economic burden of AIDS patients and played an important role in effectively controlling the AIDS epidemic, which has been praised internationally.

After an acute overdose of dolutegravir, abacavir, or lamivudine, no specific symptoms or signs other than those listed as adverse reactions have been noted.

There is no specific treatment for overdose with dolutea. If overdose occurs, the patient should receive supportive care and appropriate monitoring if necessary. Because lamivudine is dialyzable, continuous hemodialysis may be used in the treatment of overdose, but this has not been studied. It is unknown whether abacavir is eliminated by peritoneal dialysis or hemodialysis. Dolutegravir is highly bound to plasma proteins, so it is unlikely to be significantly removed using dialysis.

Recommended dosage: Adults and adolescents (weighing at least 40kg);

For adults and adolescents, the recommended dose of Dolutegra is one tablet once daily.

Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax is a fixed-dose tablet and the dose cannot be reduced.

Dolutegravir is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines.

We also remind everyone that HIV-infected patients, regardless of their race, should be screened for carrying the HLA-B*5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the RLA-B*5701 allele, he should not take products containing abacavir. Therefore, patients must obtain sufficient examination results before using it under the doctor's advice.

Recommended related hot articles: /newsDetail/85429.html